Special Issue "Angiogenesis Inhibitors"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (30 April 2011)
Prof. Dr. Domenico Ribatti
Dipartimento di Scienze Mediche di Base,Sezione di Anatomia Umana e Istologia, Università degli Studi di Bari, Piazza G. Cesare 11, Policlinico, 70124 Bari, Italy
Phone: +39 080 5478240
Fax: +39 080 5478310
The idea of targeting angiogenesis to inhibit tumor growth was proposed more than three decades ago by Judah Folkman, and since then several approaches to block or disrupt tumor angiogenesis have been explored.
Antiangiogenesis remains a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials.
Until now, the success of antiangiogenic compounds in the clinic is rather limited when given as monotherapies. This is in contrast with many preclinical results which revealed a much higher efficacy of these agents in animal models.
Prof. Dr. Domenico Ribatti
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed Open Access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 500 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- angiopoietin-2 antagonists
- antiangiogenic monoclonal antibodies
- assays to validate antiangiogenic agents
- biomarkers of response to antiangiogenic therapy
- combination of antiangiogenic therapy with other anticancer therapies
- endogenous inhibitors of angiogenesis
- genetic strategies for targeting angiogenesis
- imaging of tumor angiogenesis
- integrins as targets for antiangiogenic therapy
- metronomic low-dose antiangiogenic chemotherapy
- protein tyrosine kinase inhibitors
- targeted drug delivery to the tumor neovasculature
- thalidomide and its IMiD derivatives
- translating angiogenesis inhibitors to the clinic
Review: The Vasohibin Family
Pharmaceuticals 2010, 3(2), 433-440; doi:10.3390/ph3020433
Received: 13 January 2010; in revised form: 23 January 2010 / Accepted: 3 February 2010 / Published: 5 February 2010| Download PDF Full-text (103 KB)
Pharmaceuticals 2010, 3(3), 482-513; doi:10.3390/ph3030482
Received: 12 January 2010; in revised form: 29 January 2010 / Accepted: 2 March 2010 / Published: 8 March 2010| Download PDF Full-text (219 KB)
Review: Platelet-Derived Growth Factor (PDGF)/PDGF Receptors (PDGFR) Axis as Target for Antitumor and Antiangiogenic Therapy
Pharmaceuticals 2010, 3(3), 572-599; doi:10.3390/ph3030572
Received: 28 January 2010; in revised form: 16 February 2010 / Accepted: 9 March 2010 / Published: 11 March 2010| Download PDF Full-text (2001 KB) | Download XML Full-text
Review: Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action
Pharmaceuticals 2010, 3(4), 1241-1278; doi:10.3390/ph3041241
Received: 14 February 2010; in revised form: 20 April 2010 / Accepted: 22 April 2010 / Published: 23 April 2010| Download PDF Full-text (1390 KB)
Pharmaceuticals 2010, 3(10), 3021-3039; doi:10.3390/ph3103021
Received: 10 August 2010; in revised form: 19 September 2010 / Accepted: 25 September 2010 / Published: 28 September 2010| Download PDF Full-text (404 KB)
Pharmaceuticals 2011, 4(6), 782-793; doi:10.3390/ph4060782
Received: 25 April 2011; in revised form: 23 May 2011 / Accepted: 30 May 2011 / Published: 31 May 2011| Download PDF Full-text (369 KB) | Download XML Full-text
Article: Vasoinhibins Prevent Bradykinin-Stimulated Endothelial Cell Proliferation by Inactivating eNOS via Reduction of both Intracellular Ca2+ Levels and eNOS Phosphorylation at Ser1179
Pharmaceuticals 2011, 4(7), 1052-1069; doi:10.3390/ph4071052
Received: 29 April 2011; in revised form: 6 July 2011 / Accepted: 19 July 2011 / Published: 20 July 2011| Download PDF Full-text (476 KB) | Download XML Full-text
Review: Proteolytically Derived Endogenous Angioinhibitors Originating from the Extracellular Matrix
Pharmaceuticals 2011, 4(12), 1551-1577; doi:10.3390/ph4121551
Received: 14 October 2011; in revised form: 24 November 2011 / Accepted: 25 November 2011 / Published: 2 December 2011| Download PDF Full-text (789 KB) | Download XML Full-text
Last update: 19 July 2013